TECARTUS (Gilead Sciences Pty Ltd)
Product name
TECARTUS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
172 (255 working days)
Active ingredients
T Cells - Brexucabtagene autoleucel, cryopreserved - T - Tecartus
Registration type
Biologicals
Indication
Class 4 biological
TECARTUS is a genetically modified autologous immunocellular therapy for the treatment of patients greater than or equal to 18 years of age with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (B-ALL).